Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Corinna M. Panlilio is active.

Publication


Featured researches published by Corinna M. Panlilio.


Cellular & Molecular Biology Letters | 2007

Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression

Pavan Atluri; Kevin Morine; George P. Liao; Corinna M. Panlilio; Mark F. Berry; Vivian M. Hsu; William Hiesinger; Jeffrey E. Cohen; Y. Joseph Woo

Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy.Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis.Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750±133500 vs. 901600±143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0±4.6 vs. 1.0±1.2 ng/ml, n=5, p=0.006) and western blot (1579400±477733 vs. 943000±157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.


Circulation | 2006

Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart Failure

Y. Joseph Woo; Corinna M. Panlilio; Richard K. Cheng; George P. Liao; Pavan Atluri; Vivian M. Hsu; Jeffrey E. Cohen; Hina W. Chaudhry

Background— Heart failure is a global health concern. As a novel therapeutic strategy, the induction of endogenous myocardial regeneration was investigated by initiating cardiomyocyte mitosis by expressing the cell cycle regulator cyclin A2. Methods and Results— Lewis rats underwent left anterior descending coronary artery ligation followed by peri-infarct intramyocardial delivery of adenoviral vector expressing cyclin A2 (n =32) or empty adeno-null (n =32). Cyclin A2 expression was characterized by Western Blot and immunohistochemistry. Six weeks after surgery, in vivo myocardial function was analyzed using an ascending aortic flow probe and pressure-volume catheter. DNA synthesis was analyzed by proliferating cell nuclear antigen (PCNA), Ki-67, and BrdU. Mitosis was analyzed by phosphohistone-H3 expression. Myofilament density and ventricular geometry were assessed. Cyclin A2 levels peaked at 2 weeks and tapered off by 4 weeks. Borderzone cardiomyocyte cell cycle activation was demonstrated by increased PCNA (40.1±2.6 versus 9.3±1.1; P<0.0001), Ki-67 (46.3±7.2 versus 20.4±6.0; P<0.0001), BrdU (44.2±13.7 versus 5.2±5.2; P<0.05), and phosphohistone-H3 (12.7±1.4 versus 0±0; P<0.0001) positive cells/hpf. Cyclin A2 hearts demonstrated increased borderzone myofilament density (39.8±1.1 versus 31.8±1.0 cells/hpf; P=0.0011). Borderzone wall thickness was greater in cyclin A2 hearts (1.7±0.4 versus 1.4±0.04 mm; P<0.0001). Cyclin A2 animals manifested improved hemodynamics: Pmax (70.6±8.9 versus 60.4±11.8 mm Hg; P=0.017), max dP/dt (3000±588 versus 2500±643 mm Hg/sec; P<0.05), preload adjusted maximal power (5.75±4.40 versus 2.75±0.98 mWatts/&mgr;L2; P<0.05), and cardiac output (26.8±3.7 versus 22.7±2.6 mL/min; P=0.004). Conclusions— A therapeutic strategy of cyclin A2 expression via gene transfer induced cardiomyocyte cell cycle activation yielded increased borderzone myofilament density and improved myocardial function. This approach of inducing endogenous myocardial regeneration provides proof-of-concept evidence that cyclin A2 may ultimately serve as an efficient, alternative therapy for heart failure.


The Journal of Thoracic and Cardiovascular Surgery | 2008

Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function

Pavan Atluri; Corinna M. Panlilio; George P. Liao; Eric Suarez; Ryan C. McCormick; William Hiesinger; Jeffrey E. Cohen; Maximilian J. Smith; Abha B. Patel; Wei Feng; Y. Joseph Woo

OBJECTIVE A significant number of patients have coronary artery disease that is not amenable to traditional revascularization. Prospective, randomized clinical trials have demonstrated therapeutic benefits with transmyocardial laser revascularization in this cohort. The molecular mechanisms underlying this therapy, however, are poorly understood. The focus of this study was evaluation of the proposed vasculogenic mechanisms involved in transmyocardial laser revascularization. METHODS Male Yorkshire pigs (30-35 kg, n = 25) underwent left thoracotomy and placement of ameroid constrictors around the proximal left circumflex coronary artery. During the next 4 weeks, a well-defined region of myocardial ischemia developed, and the animals underwent a redo left thoracotomy. The animals were randomly assigned to sham treatment (thoracotomy only, control, n = 11) or transmyocardial laser revascularization of hibernating myocardium with a holmium:yttrium-aluminum-garnet laser (n = 14). After an additional 4 weeks, the animals underwent median sternotomy, echocardiographic analysis of wall motion, and hemodynamic analysis with an ascending aortic flow probe and pulmonary artery catheter. The hearts were explanted for molecular analysis. RESULTS Molecular analysis demonstrated statistically significant increases in the proangiogenic proteins nuclear factor kappaB (42 +/- 27 intensity units vs 591 +/- 383 intensity units, P = .03) and angiopoietin 1 (0 +/- 0 intensity units vs 241 +/- 87 intensity units, P = .003) relative to sham control values with transmyocardial laser revascularization within the ischemic myocardium. There were also increases in vasculogenesis (18.8 +/- 8.7 vessels/high-power field vs 31.4 +/- 10.2 vessels/high-power field, P = .02), and perfusion (0.028 +/- 0.009 microm3 blood/microm3 tissue vs 0.044 +/- 0.004 microm3 blood/microm3 tissue, P = .01). Enhanced myocardial viability was demonstrated by increased myofilament density (40.7 +/- 8.5 cardiomyocytes/high-power field vs 50.8 +/- 7.5 cardiomyocytes/high-power field, P = .03). Regional myocardial function within the treated territory demonstrated augmented contractility. Global hemodynamic function was significantly improved relative to the control group with transmyocardial laser revascularization (cardiac output 2.1 +/- 0.2 L/min vs 2.7 +/- 0.2 L/min, P = .007, mixed venous oxygen saturation 64.7% +/- 3.6% vs 76.1% +/- 3.4%, P = .008). CONCLUSION Transmyocardial laser revascularization with the holmium-YAG laser enhances perfusion, with resultant improvement in myocardial contractility.


Heart Lung and Circulation | 2010

Acute Myocardial Rescue with Endogenous Endothelial Progenitor Cell Therapy

Pavan Atluri; Corinna M. Panlilio; George P. Liao; William Hiesinger; David A. Harris; Ryan C. McCormick; Jeffrey E. Cohen; Tao Jin; Wei Feng; Rebecca D. Levit; Nianguo Dong; Y. Joseph Woo

PURPOSE Post-myocardial infarction heart failure is a major health concern with limited therapy. Molecular revascularisation utilising granulocyte-macrophage colony stimulating factor (GMCSF) mediated endothelial progenitor cell (EPC) upregulation and stromal cell derived factor-1α (SDF) mediated myocardial EPC chemokinesis, may prevent myocardial loss and adverse remodelling. Vasculogenesis, viability, and haemodynamic improvements following therapy were investigated. PROCEDURES Lewis rats (n=91) underwent LAD ligation and received either intramyocardial SDF and subcutaneous GMCSF or saline injections at the time of infarction. Molecular and haemodynamic assessments were performed at pre-determined time points following ligation. FINDINGS SDF/GMCSF therapy upregulated EPC density as shown by flow cytometry (0.12±0.02% vs. 0.06±0.01% circulating lymphocytes, p=0.005), 48hours following infarction. A marked increase in perfusion was evident eight weeks after therapy, utilising confocal angiography (5.02±1.7×10(-2)μm(3)blood/μm(3)myocardial tissue vs. 2.03±0.710(-2)μm(3)blood/μm(3)myocardial tissue, p=0.00004). Planimetric analysis demonstrated preservation of wall thickness (0.98±0.09mm vs. 0.67±0.06mm, p=0.003) and ventricular diameter (7.81±0.99mm vs. 9.41±1.1mm, p=0.03). Improved haemodynamic function was evidenced by echocardiography and PV analysis (ejection fraction: 56.4±18.1% vs. 25.3±15.6%, p=0.001; pre-load adjusted maximal power: 6.6±2.6mW/μl(2) vs. 2.7±1.4mW/μl(2), p=0.01). CONCLUSION Neovasculogenic therapy with GMCSF-mediated EPC upregulation and SDF-mediated EPC chemokinesis maybe an effective therapy for infarct modulation and preservation of myocardial function following acute myocardial infarction.


Asian Cardiovascular and Thoracic Annals | 2006

Off-Pump Revascularization for Significant Left Ventricular Dysfunction

Y. Joseph Woo; Todd J. Grand; George P. Liao; Corinna M. Panlilio

Left ventricular dysfunction is a predictor of perioperative morbidity and mortality in on-pump coronary artery bypass grafting. Obligatory global myocardial ischemia and injury induced during crossclamping as well as adverse systemic effects of cardiopulmonary bypass may induce a disproportionately greater overall physiologic insult in patients with poor ventricular function. All patients undergoing nonemergency off-pump coronary artery bypass by a single surgeon during an 18-month period were retrospectively analyzed. Two groups with preoperative ejection fraction classified as poor (10%–35%; n = 31) or normal (55%–80%; n = 60) were compared. The mean ejection fractions were 26% ± 1% and 63% ± 1% respectively, p < 0.000001. In those with significant left ventricular dysfunction, there were 2.8 ± 0.1 grafts per patient, time to extubation was 8.4 ± 1.2 hours, and discharge was after 4.9 ± 0.6 days. These results were statistically equivalent to those in the group with normal left ventricular function. There was no intraaortic balloon pump insertion or mortality in either group. This technique provides an effective means of safely revascularizing patients with significant left ventricular dysfunction, and it may provide a valuable alternative approach in patients with ischemic cardiomyopathy.


The Annals of Thoracic Surgery | 2006

Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.

Pavan Atluri; George P. Liao; Corinna M. Panlilio; Vivian M. Hsu; Matthew J. Leskowitz; Kevin Morine; Jeffrey E. Cohen; Mark F. Berry; Erik E. Suarez; Danielle A. Murphy; William M. F. Lee; Timothy J. Gardner; H. Lee Sweeney; Y. Joseph Woo


The Journal of Thoracic and Cardiovascular Surgery | 2007

Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2

Y. Joseph Woo; Corinna M. Panlilio; Richard K. Cheng; George P. Liao; Erik E. Suarez; Pavan Atluri; Hina W. Chaudhry


Heart Lung and Circulation | 2006

Fructose 1,6-diphosphate administration attenuates post-ischemic ventricular dysfunction.

Jeffrey E. Cohen; Pavan Atluri; Matthew D. Taylor; Todd J. Grand; George P. Liao; Corinna M. Panlilio; Erik E. Suarez; Suzanne Zentko; Vivian M. Hsu; Mark F. Berry; Maximillian J. Smith; Timothy J. Gardner; H. Lee Sweeney; Y. Joseph Woo


Journal of Cardiac Failure | 2006

Endothelial Progenitor Cell Targeting to Ischemic Myocardium Attenuates Hypoxia and Enhances Cardiomyocyte Viability and Function

Pavan Atluri; Kevin Morine; George P. Liao; Corinna M. Panlilio; Y. Joseph Woo


Circulation | 2006

Abstract 1987: Acute Myocardial Rescue with Endogenous Endothelial Progenitor Cell Therapy

Pavan Atluri; Corinna M. Panlilio; George P. Liao; Erik E. Suarez; Jeffrey E. Cohen; John B Hye; Nianguo Dong; Y. Joseph Woo

Collaboration


Dive into the Corinna M. Panlilio's collaboration.

Top Co-Authors

Avatar

George P. Liao

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pavan Atluri

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vivian M. Hsu

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Erik E. Suarez

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Kevin Morine

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William Hiesinger

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge